Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.38 |
| ▸ | CCL5 | P13501 | 10/20 | 0.37 |
| ▸ | CCR5 | P51681 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5663302 | 1.00 | PTPN11 (0.39) | PTPN11HCRTR1HCRTR2CCL5CCR5 | |
| SCHEMBL4697487 | 0.90 | PTPN11 (0.39) | PTPN11HCRTR1HCRTR2CCL5CCR5 | |
| SCHEMBL5660276 | 0.88 | PTPN11 (0.39) | PTPN11HCRTR1HCRTR2CCL5CCR5 | |
| SCHEMBL5659884 | 0.86 | MCHR1 (0.39) | PTPN11CCL5CCR5 | |
| SCHEMBL4691440 | 0.85 | CCR5 (0.41) | CCL5CCR5 | |
| SCHEMBL5659665 | 0.83 | CCL5 (0.38) | CCL5CCR5 | |
| SCHEMBL5660860 | 0.83 | PTPN11 (0.38) | PTPN11CCL5CCR5 | |
| SCHEMBL4695015 | 0.83 | CCR5 (0.40) | CCL5CCR5 | |
| SCHEMBL4694907 | 0.83 | CCL5 (0.43) | CCL5CCR5 | |
| SCHEMBL4694360 | 0.82 | CCL5 (0.39) | CCL5CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191335-A1 | 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191335-A1 | 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease | CCR5, CXCR1, CXCR3 | PTPN11 697/4885HCRTR1 150/4885HCRTR2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.